This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2023 May 1;141(5):466-467.

doi: 10.1001/jamaophthalmol.2023.0850.

Comparison of Water-Free Commercially Available Cyclosporine Ophthalmic Preparations-Different, but the Same

Andrea Naranjo Lozano¹, Alice Shen¹, Jennifer Rose-Nussbaumer¹

Affiliations

PMID: 37022711
DOI: 10.1001/jamaophthalmol.2023.0850

Comment

Comparison of Water-Free Commercially Available Cyclosporine Ophthalmic Preparations-Different, but the Same

Andrea Naranjo Lozano et al. JAMA Ophthalmol. 2023.

. 2023 May 1;141(5):466-467.

doi: 10.1001/jamaophthalmol.2023.0850.

Authors

Andrea Naranjo Lozano¹, Alice Shen¹, Jennifer Rose-Nussbaumer¹

Affiliation

¹ Byers Eye Institute, Stanford University, Palo Alto, California.

PMID: 37022711
DOI: 10.1001/jamaophthalmol.2023.0850

No abstract available

PubMed Disclaimer

Comment on

Efficacy and Safety of a Water-Free Topical Cyclosporine, 0.1%, Solution for the Treatment of Moderate to Severe Dry Eye Disease: The ESSENCE-2 Randomized Clinical Trial.
Akpek EK, Wirta DL, Downing JE, Tauber J, Sheppard JD, Ciolino JB, Meides AS, Krösser S. Akpek EK, et al. JAMA Ophthalmol. 2023 May 1;141(5):459-466. doi: 10.1001/jamaophthalmol.2023.0709. JAMA Ophthalmol. 2023. PMID: 37022717 Free PMC article.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Silverchair Information Systems